GLICLAZIDE MYLAN PHARMA 60 mg, modified-release tablet 30 tablets
Active ingredients: Gliclazide
Commercialized according to BDPMDispensing in France: Prescription only
Modified-release tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- GLICLAZIDE MYLAN PHARMA 60 mg, comprimé à libération modifiée
- Pharmaceutical form
- comprimé à libération modifiée
- Route of administration
- orale
- Presentation description
- plaquette(s) polyamide aluminium PVC-Aluminium de 30 comprimé(s)
- Marketing authorisation holder
- MYLAN SAS
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 4 Sept 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65571438CIP72691422CIP133400926914226Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| GLICLAZIDEcomprimé | 60 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.